The Potential Role of the T2 Ribonucleases in TME-Based Cancer Therapy

Abstract

In recent years, there has been a growing interest in developing innovative anticancer therapies targeting the tumor microenvironment (TME). The TME is a complex and dynamic milieu surrounding the tumor mass, consisting of various cellular and molecular components, including those from the host organism, endowed with the ability to significantly influence cancer development and progression. Processes such as angiogenesis, immune evasion, and metastasis are crucial targets in the search for novel anticancer drugs. Thus, identifying molecules with “multi-tasking” properties that can counteract cancer cell growth at multiple levels represents a relevant but still unmet clinical need. Extensive research over the past two decades has revealed a consistent anticancer activity for several members of the T2 ribonuclease family, found in evolutionarily distant species. Initially, it was believed that T2 ribonucleases mainly acted as anticancer agents in a cell-autonomous manner. However, further investigation uncovered a complex and independent mechanism of action that operates at a non-cell-autonomous level, affecting crucial processes in TME-induced tumor growth, such as angiogenesis, evasion of immune surveillance, and immune cell polarization. Here, we review and discuss the remarkable properties of ribonucleases from the T2 family in the context of “multilevel” oncosuppression acting on the TME.

Glucocorticoids in lung cancer: Navigating the balance between immunosuppression and therapeutic efficacy

“…Tumor cells constitute the core component of the TME in LC, characterized by autonomous growth, unrestricted division, and evasion of immune surveillance [ 5 ]. LC cells can be categorized into several histological types, such as adenocarcinoma, squamous cell carcinoma, and small-cell LC [ 6 ].…”